Can-Fite BioPharma Reports Namodenoson Success in Liver Cirrhosis
Ticker: CANF · Form: 6-K · Filed: Jul 1, 2024 · CIK: 1536196
| Field | Detail |
|---|---|
| Company | Can-Fite Biopharma LTD. (CANF) |
| Form Type | 6-K |
| Filed Date | Jul 1, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | mixed |
Sentiment: mixed
Topics: clinical-trial-update, drug-development, press-release
TL;DR
Can-Fite's Namodenoson shows patient improvement in decompensated liver cirrhosis trial.
AI Summary
On July 1, 2024, Can-Fite BioPharma Ltd. announced positive results from a patient treated with Namodenoson for decompensated liver cirrhosis. The press release, filed as part of a 6-K, details an improvement in the patient's condition.
Why It Matters
This filing highlights potential progress in treating decompensated liver cirrhosis, a serious condition with limited treatment options, using Can-Fite's drug Namodenoson.
Risk Assessment
Risk Level: medium — The filing reports on a single patient's improvement, which is early-stage data and may not be representative of broader efficacy or safety.
Key Players & Entities
- Can-Fite BioPharma Ltd. (company) — Registrant
- Namodenoson (drug) — Treatment
- July 1, 2024 (date) — Press Release Date
FAQ
What specific improvements were observed in the patient with decompensated liver cirrhosis?
The press release, filed on July 1, 2024, states there was an 'Improvement in Patient with Decompensated Liver Cirrhosis Upon Treatment with Namodenoson,' but does not detail specific metrics in this 6-K filing.
What is the status of Namodenoson's development for liver cirrhosis?
This 6-K filing reports on a single patient's positive outcome, suggesting ongoing investigation into Namodenoson's potential for treating decompensated liver cirrhosis.
When was this press release issued?
The press release titled 'Improvement in Patient with Decompensated Liver Cirrhosis Upon Treatment with Namodenoson' was issued on July 1, 2024.
What form is this filing?
This filing is a Form 6-K, which is a Report of Foreign Private Issuer.
What is the principal executive office address for Can-Fite BioPharma Ltd.?
The principal executive offices are located at 26 Ben Gurion Street, Ramat Gan, 5257346, Israel.
Filing Stats: 195 words · 1 min read · ~1 pages · Grade level 11.1 · Accepted 2024-07-01 07:05:02
Filing Documents
- ea0208775-6k_canfite.htm (6-K) — 9KB
- ea020877501ex99-1_can.htm (EX-99.1) — 13KB
- logo.jpg (GRAPHIC) — 13KB
- 0001213900-24-057535.txt ( ) — 42KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: July 1, 2024 By: /s/ Motti Farbstein Motti Farbstein Chief Executive Officer and Chief Financial Officer 2